Naoki Okamura, Astellas president and CEO

Astel­las bags prostate can­cer drug in $175M buy­out as Xtan­di ap­proach­es patent cliff

Astel­las is shelling out $175 mil­lion in cash to buy Pro­pel­la Ther­a­peu­tics and its Phase I prostate can­cer ther­a­py that puts a twist on a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.